Showing 41-50 of 2403 results for "".
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t
- Dark Beer? Green Cabbage? The Scoop on St. Patrick's Day's Hidden Beauty Secretshttps://practicaldermatology.com/news/dark-beer-green-cabbage-the-scoop-on-st-patricks-days-hidden-beauty-secrets/2458647/It’s easy to be green on St. Patrick’s day (March 17th), but many skin care companies are now carrying this torch 365 days a year. And going green isn’t the only St. Paddy’s day tradition that promises beauty benefits. Companies such as
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat p
- Demystifying Itch: Does S. aureus Kickstart a Molecular Chain Reaction That Culminates in the Urge to Scratch?https://practicaldermatology.com/news/demystifying-itch-does-s-aureus-kickstart-a-molecular-chain-reaction-that-culminates-in-the-urge-to-scratch/2462148/Staphylococcus aureus may cause itch by acting directly on nerve cells. The findings, based on research in mice and in human cells, are reported Nov. 22 in Cell. In eczema and atopic dermatitis, the equilibrium of microorganisms that keep skin he
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- Advanced Aesthetic Technologies, Inc.’s Algeness Named Top Finalist in Terra2 Solution Skin Health Innovation Competitionhttps://practicaldermatology.com/news/advanced-aesthetic-technologies-incs-algeness-named-top-finalist-in-terra2-solution-skin-health-innovation-competition/2460708/Advanced Aesthetic Technologies, Inc. (AAT) and Algeness are finalists in the recent Terra2 Solutions Skin Health Innovation Competition. Algeness is a patented family of fully resorbable injectable gel implant dermal fillers that are 100% natural and based on purified agarose with
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like